Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 139

1.

Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer.

Pierre F, Chua PC, O'Brien SE, Siddiqui-Jain A, Bourbon P, Haddach M, Michaux J, Nagasawa J, Schwaebe MK, Stefan E, Vialettes A, Whitten JP, Chen TK, Darjania L, Stansfield R, Bliesath J, Drygin D, Ho C, Omori M, Proffitt C, Streiner N, Rice WG, Ryckman DM, Anderes K.

Mol Cell Biochem. 2011 Oct;356(1-2):37-43. doi: 10.1007/s11010-011-0956-5. Epub 2011 Jul 14.

PMID:
21755459
[PubMed - indexed for MEDLINE]
2.

CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.

Siddiqui-Jain A, Drygin D, Streiner N, Chua P, Pierre F, O'Brien SE, Bliesath J, Omori M, Huser N, Ho C, Proffitt C, Schwaebe MK, Ryckman DM, Rice WG, Anderes K.

Cancer Res. 2010 Dec 15;70(24):10288-98. doi: 10.1158/0008-5472.CAN-10-1893.

PMID:
21159648
[PubMed - indexed for MEDLINE]
Free Article
3.

Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer.

Pierre F, Chua PC, O'Brien SE, Siddiqui-Jain A, Bourbon P, Haddach M, Michaux J, Nagasawa J, Schwaebe MK, Stefan E, Vialettes A, Whitten JP, Chen TK, Darjania L, Stansfield R, Anderes K, Bliesath J, Drygin D, Ho C, Omori M, Proffitt C, Streiner N, Trent K, Rice WG, Ryckman DM.

J Med Chem. 2011 Jan 27;54(2):635-54. doi: 10.1021/jm101251q. Epub 2010 Dec 21.

PMID:
21174434
[PubMed - indexed for MEDLINE]
4.

Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer.

Battistutta R, Cozza G, Pierre F, Papinutto E, Lolli G, Sarno S, O'Brien SE, Siddiqui-Jain A, Haddach M, Anderes K, Ryckman DM, Meggio F, Pinna LA.

Biochemistry. 2011 Oct 4;50(39):8478-88. doi: 10.1021/bi2008382. Epub 2011 Sep 7.

PMID:
21870818
[PubMed - indexed for MEDLINE]
5.

Druggability of the CK2 inhibitor CX-4945 as an anticancer drug and beyond.

Kim J, Kim SH.

Arch Pharm Res. 2012 Aug;35(8):1293-6. doi: 10.1007/s12272-012-0800-9.

PMID:
22941473
[PubMed - indexed for MEDLINE]
6.

Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth.

Drygin D, Lin A, Bliesath J, Ho CB, O'Brien SE, Proffitt C, Omori M, Haddach M, Schwaebe MK, Siddiqui-Jain A, Streiner N, Quin JE, Sanij E, Bywater MJ, Hannan RD, Ryckman D, Anderes K, Rice WG.

Cancer Res. 2011 Feb 15;71(4):1418-30. doi: 10.1158/0008-5472.CAN-10-1728. Epub 2010 Dec 15.

PMID:
21159662
[PubMed - indexed for MEDLINE]
Free Article
7.

CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy.

Siddiqui-Jain A, Bliesath J, Macalino D, Omori M, Huser N, Streiner N, Ho CB, Anderes K, Proffitt C, O'Brien SE, Lim JK, Von Hoff DD, Ryckman DM, Rice WG, Drygin D.

Mol Cancer Ther. 2012 Apr;11(4):994-1005. doi: 10.1158/1535-7163.MCT-11-0613. Epub 2012 Jan 20.

PMID:
22267551
[PubMed - indexed for MEDLINE]
Free Article
8.

Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastoma.

Zheng Y, McFarland BC, Drygin D, Yu H, Bellis SL, Kim H, Bredel M, Benveniste EN.

Clin Cancer Res. 2013 Dec 1;19(23):6484-94. doi: 10.1158/1078-0432.CCR-13-0265. Epub 2013 Sep 13.

PMID:
24036851
[PubMed - indexed for MEDLINE]
9.

Anti-androgen receptor activity of apoptotic CK2 inhibitor CX4945 in human prostate cancer LNCap cells.

Ryu BJ, Baek SH, Kim J, Bae SJ, Chang SY, Heo JN, Lee H, Lee SY, Kim SH.

Bioorg Med Chem Lett. 2012 Sep 1;22(17):5470-4. doi: 10.1016/j.bmcl.2012.07.031. Epub 2012 Jul 14.

PMID:
22832316
[PubMed - indexed for MEDLINE]
10.

Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer.

Drygin D, Ho CB, Omori M, Bliesath J, Proffitt C, Rice R, Siddiqui-Jain A, O'Brien S, Padgett C, Lim JK, Anderes K, Rice WG, Ryckman D.

Biochem Biophys Res Commun. 2011 Nov 11;415(1):163-7. doi: 10.1016/j.bbrc.2011.10.046. Epub 2011 Oct 18.

PMID:
22027148
[PubMed - indexed for MEDLINE]
11.

Salicylaldehyde derivatives as new protein kinase CK2 inhibitors.

Prudent R, López-Ramos M, Moucadel V, Barette C, Grierson D, Mouawad L, Florent JC, Lafanechère L, Schmidt F, Cochet C.

Biochim Biophys Acta. 2008 Dec;1780(12):1412-20. doi: 10.1016/j.bbagen.2008.06.010. Epub 2008 Jul 7.

PMID:
18674590
[PubMed - indexed for MEDLINE]
Free Article
12.

Antitumor activity of pyridocarbazole and benzopyridoindole derivatives that inhibit protein kinase CK2.

Prudent R, Moucadel V, Nguyen CH, Barette C, Schmidt F, Florent JC, Lafanechère L, Sautel CF, Duchemin-Pelletier E, Spreux E, Filhol O, Reiser JB, Cochet C.

Cancer Res. 2010 Dec 1;70(23):9865-74. doi: 10.1158/0008-5472.CAN-10-0917. Epub 2010 Nov 30.

PMID:
21118972
[PubMed - indexed for MEDLINE]
Free Article
13.

Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling.

Buontempo F, Orsini E, Martins LR, Antunes I, Lonetti A, Chiarini F, Tabellini G, Evangelisti C, Evangelisti C, Melchionda F, Pession A, Bertaina A, Locatelli F, McCubrey JA, Cappellini A, Barata JT, Martelli AM.

Leukemia. 2014 Mar;28(3):543-53. doi: 10.1038/leu.2013.349. Epub 2013 Nov 20.

PMID:
24253024
[PubMed - indexed for MEDLINE]
14.

Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity.

Quotti Tubi L, Gurrieri C, Brancalion A, Bonaldi L, Bertorelle R, Manni S, Pavan L, Lessi F, Zambello R, Trentin L, Adami F, Ruzzene M, Pinna LA, Semenzato G, Piazza F.

J Hematol Oncol. 2013 Oct 12;6:78. doi: 10.1186/1756-8722-6-78.

PMID:
24283803
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930.

Yap TA, Walton MI, Hunter LJ, Valenti M, de Haven Brandon A, Eve PD, Ruddle R, Heaton SP, Henley A, Pickard L, Vijayaraghavan G, Caldwell JJ, Thompson NT, Aherne W, Raynaud FI, Eccles SA, Workman P, Collins I, Garrett MD.

Mol Cancer Ther. 2011 Feb;10(2):360-71. doi: 10.1158/1535-7163.MCT-10-0760. Epub 2010 Dec 29.

PMID:
21191045
[PubMed - indexed for MEDLINE]
Free Article
16.

Inhibition of protein kinase CK2 reduces Cyp24a1 expression and enhances 1,25-dihydroxyvitamin D(3) antitumor activity in human prostate cancer cells.

Luo W, Yu WD, Ma Y, Chernov M, Trump DL, Johnson CS.

Cancer Res. 2013 Apr 1;73(7):2289-97. doi: 10.1158/0008-5472.CAN-12-4119. Epub 2013 Jan 28.

PMID:
23358686
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Tirucallic acids are novel pleckstrin homology domain-dependent Akt inhibitors inducing apoptosis in prostate cancer cells.

Estrada AC, Syrovets T, Pitterle K, Lunov O, Büchele B, Schimana-Pfeifer J, Schmidt T, Morad SA, Simmet T.

Mol Pharmacol. 2010 Mar;77(3):378-87. doi: 10.1124/mol.109.060475. Epub 2009 Dec 16.

PMID:
20018812
[PubMed - indexed for MEDLINE]
Free Article
18.

Discovery and design of tricyclic scaffolds as protein kinase CK2 (CK2) inhibitors through a combination of shape-based virtual screening and structure-based molecular modification.

Sun H, Xu X, Wu X, Zhang X, Liu F, Jia J, Guo X, Huang J, Jiang Z, Feng T, Chu H, Zhou Y, Zhang S, Liu Z, You Q.

J Chem Inf Model. 2013 Aug 26;53(8):2093-102. doi: 10.1021/ci400114f. Epub 2013 Aug 12.

PMID:
23937544
[PubMed - indexed for MEDLINE]
19.

Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer.

Chung S, Suzuki H, Miyamoto T, Takamatsu N, Tatsuguchi A, Ueda K, Kijima K, Nakamura Y, Matsuo Y.

Oncotarget. 2012 Dec;3(12):1629-40.

PMID:
23283305
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.

Kulp SK, Chen CS, Wang DS, Chen CY, Chen CS.

Clin Cancer Res. 2006 Sep 1;12(17):5199-206.

PMID:
16951239
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk